All In Biotech

Drug Trial Radar · NCT00314171

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: Nov 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 437 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

437

Actual

Start

Oct 2005

Primary completion

Aug 2007

Study completion Aug 2007

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Apr 13, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.

Conditions

  • Open-angle Glaucoma
  • Ocular Hypertension

Interventions

  • Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspensionDrug

    One drop in the study eye(s) twice daily for 12 months

  • Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)Drug

    One drop in the study eye(s) twice daily for 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean IOP

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.